OUTLOOK THERAPEUTICS INC
🔔 Watch stock
Assessment
Our Rating
A journalistic assessment by our editorial team at the time of the deep dive — it rates the company, not the entry point. Not investment advice and not a solicitation to buy or sell.
We found at least one documented issue that threatens the company itself — regardless of how the stock is currently valued.
Why this colour
The approval is a genuine milestone and removes the single largest risk — but it removes neither the going-concern notice, nor the $30.2 million of debt maturing from late 2026, nor the ongoing dilution. The bet on the regulator has become a bet on the financing; anyone staying invested should size the position against a capital raise on weak terms. The decision is yours.
What the thesis turns on
Assessment: Opportunities & Risks
At the fourth attempt, Outlook Therapeutics achieved what had defeated it three times: LYTENAVA has been approved in the United States since July 24, 2026. The binary regulatory risk is settled — and the question shifts to the cash box: $7.75 million as of March 31, 2026, $30.2 million of debt, a share count that more than tripled in nine months, and an authorized share pipe doubled to 600 million shortly before the yes. Not investment advice.
Approval
The FDA approved LYTENAVA on July 24, 2026 — at the fourth attempt and five days ahead of its own goal date. The single largest risk in the stock is settled, and the EU (May 2024) and UK (July 2024) approvals remain in place.
Label & competition
Only wet AMD is approved, dosing is monthly (1.25 mg roughly every 28 days) with no interval extension, and the label documents the missed non-inferiority margin of NORSE EIGHT. The twelve-year exclusivity blocks biosimilars, not repackaged Avastin, which accounts for 66.3 percent of new patient starts per Outlook's own annual report.
Liquidity
Going-concern notice in the quarterly report: $7.75 million of cash (March 31, 2026) against roughly $11.8 million of operating outflow per quarter, plus $30.2 million of debt maturing December 31, 2026 and June 16, 2027 — rank 1 in our "Insolvency Radar" (live query July 27, 2026).
Dilution
Share count from 53.9 million (September 30, 2025) to 187.0 million (June 22, 2026); authorized shares raised from 260 to 600 million on July 16, 2026, a 1-for-10 to 1-for-50 reverse split authorized, and the resale of 17,258,065 shares registered on July 21, 2026.
Launch & reimbursement
The European track record is the warning from inside the house: $1.4 million of revenue in fiscal 2025 and negative net revenue in the first half of fiscal 2026 (−$1.08 million); Germany's benefit assessment of October 16, 2025 found no proven added benefit while assigning the highest first-year drug costs in the comparator set. The U.S. sales organization has yet to be built, with 17 full-time employees and no published price as of July 27, 2026.
Governance
Three days before the approval, the compensation committee approved cash bonuses totaling $620,000, payable only upon FDA approval by July 31, 2026 — roughly 8 percent of the cash position of March 31, 2026, in a company carrying a going-concern notice (8-K of July 24, 2026, Item 5.02).
Worth Noting
Cash runway computed with the same formula as our scanner: $7.75 million of cash (March 31, 2026) divided by roughly $11.8 million of average quarterly operating outflow (last four reported quarters). Since April 2026, $4.5 million net and about $5.0 million gross arrived from two placements; per management explicitly not sufficient for twelve months.
Next checkpoints: the quarterly report on August 13, 2026 (cash line and going-concern paragraph) and the U.S. launch announced for "before year-end", with the first published price.
The price had largely front-run the approval: from a closing price of $0.27 on May 20, 2026 to $1.405 on July 24, 2026; on approval day itself, 6.4 percent was left after an intraday range of $1.12 to $1.75 on roughly 55.6 million shares traded.
The most recently visible analyst price targets ($0.50 / $1.61 / $10.00) all predate the approval; the frequently cited average near $5.50 emerges from dispersion, not agreement.
Stock Watch
This analysis is as of August 26, 2026. Stock Watch will tell you what's changed at OTLK since then.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 0.1981 $ to 2.50 $ · Last price: 0.681 $ (As of: September 17, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/18/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Biotechnology
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| OUTLOOK THERAPEUTICS INC OTLK | 0.1 | – | -4.1 | -360.8 | – | 730.9 | -33.2 |
| Vertex Pharmaceuticals Inc VRTX | 130.6 | 31.3 | 24.5 | 55.0 | 38.1 | 9.6 | 33.4 |
| Regeneron Pharmaceuticals Inc REGN | 82.0 | 19.9 | 13.1 | 44.5 | 20.7 | 1.0 | 35.5 |
| Moderna Inc MRNA | 62.7 | – | 4.6 | -66.0 | -131.1 | -39.2 | 532.3 |
| argenx NV ARGX | 61.9 | 38.1 | 34.2 | 59.1 | 32.0 | 89.6 | 30.9 |
| Revolution Medicines Inc RVMD | 40.9 | – | -9.7 | -174,708.6 | 0.0 | -100.0 | 338.3 |
| BeiGene, Ltd. ONC | 40.0 | 63.1 | 34.1 | 88.9 | 19.1 | 40.2 | 6.4 |
| Alnylam Pharmaceuticals Inc ALNY | 32.6 | 61.8 | 28.4 | 79.7 | 23.0 | 65.2 | -48.1 |
| Royalty Pharma Plc RPRX | 32.5 | 31.8 | 19.6 | 95.8 | 100.3 | 5.1 | 68.6 |
| Median of companies shown | 40.9 | 34.9 | 19.6 | 55.0 | 21.8 | 9.6 | 33.4 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 3 | -51 | -53 | -495.46 | -45 | -5 | 24 |
| 2017 | 4 | -36 | -39 | -258.54 | -16 | -31 | 21 |
| 2018 | 3 | -30 | -30 | -85.00 | -33 | -21 | 22 |
| 2019 | 8 | -36 | -35 | -37.96 | -32 | -11 | 17 |
| 2020 | 6 | -35 | -35 | -9.71 | -32 | 3 | 20 |
| 2021 | 0 | -52 | -53 | -6.96 | -54 | 5 | 23 |
| 2022 | 0 | -63 | -66 | -6.23 | -57 | 9 | 29 |
| 2023 | 0 | -53 | -59 | -4.72 | -43 | -14 | 32 |
| 2024 | 0 | -72 | -75 | -4.06 | -69 | -73 | 29 |
| 2025 | 1 | -67 | -62 | -2.45 | -52 | -32 | 19 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.12 | – | 0 | – | 10,222.40 | -11 | -11 |
| 2025: Q1 | -0.31 | – | 0 | – | – | -17 | -17 |
| 2025: Q2 | -0.14 | -145.40 | 2 | – | -1,339.10 | -12 | -12 |
| 2025: Q3 | -0.09 | -333.60 | 0 | -154.10 | – | -12 | -12 |
| 2025: Q4 | -0.16 | -232.70 | -1 | -810.60 | – | -15 | -15 |
| 2026: Q1 | -0.03 | – | 0 | – | -3,506.30 | -8 | -8 |
| 2026: Q2 | -0.15 | -7.10 | – | – | – | -21 | -21 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 14 of our scanner strategies — each hit links to the scanner.
Quality & Balance Sheet
Momentum & Trend
- Above the 50- & 200-SMA
- High ADR (≥5%)
- Qullamaggie: Top Gainers 1M
- Qullamaggie: Top Gainers 3M
- RS Leader (≥90)
- Richard Moglen: Top Performers 3/6 Month
- Stan Weinstein: Stage 3
Research
Risk & Weakness
- Bankruptcy Study: Stacked Warning Signals
- Going Concern (Distress Proxy)
- Insolvency Radar: Cash Running Low
- Mike Webster: Overextended (Webby RSI)
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 09/30/2026 | -0.44 | -0.45 – -0.42 | 1 | 77.0% | 2 |
| 09/30/2027 | -0.12 | -0.27 – -0.03 | 44 | 72.4% | 3 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Free cash flow over the past twelve months is negative, which rules out a serious reverse calculation. Any growth rate only makes a negative cash flow more negative; no present value comes out of it. What the price reflects here is therefore not a stream of cash flows, but the expectation that there will be one at all.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Outlook Therapeutics ist ein Ophthalmologie-Biotech ohne KI-Umsatzquelle; beide 10-Ks bestätigen aber ausdrücklich, dass Mitarbeiter generative KI für ihre Arbeit einsetzen und ein Verzicht darauf das Geschäft weniger effizient machen und Wettbewerbsnachteile bringen würde.
View the full file — quotes, sources, reviewed filings
„Our employees and personnel use generative artificial intelligence, or AI, technologies to perform their work, and the disclosure and use of personal data in generative AI technologies is subject to various privacy laws and other privacy obligations."
Unsere Mitarbeiter und unser Personal nutzen generative Künstliche-Intelligenz-Technologien (KI), um ihre Arbeit zu verrichten, und die Offenlegung und Nutzung personenbezogener Daten in generativen KI-Technologien unterliegt verschiedenen Datenschutzgesetzen und anderen Datenschutzpflichten.
10-K · 2025-12-19 · View SEC filing
„If we are unable to use generative AI, it could make our business less efficient and result in competitive disadvantages."
Wenn wir generative KI nicht nutzen können, könnte das unser Geschäft weniger effizient machen und zu Wettbewerbsnachteilen führen.
10-K · 2025-12-19 · View SEC filing
„Our employees and personnel use generative artificial intelligence, or AI, technologies to perform their work, and the disclosure and use of personal data in generative AI technologies is subject to various privacy laws and other privacy obligations."
Unsere Mitarbeiter und unser Personal nutzen generative Künstliche-Intelligenz-Technologien (KI), um ihre Arbeit zu verrichten, und die Offenlegung und Nutzung personenbezogener Daten in generativen KI-Technologien unterliegt verschiedenen Datenschutzgesetzen und anderen Datenschutzpflichten.
10-K · 2024-12-27 · View SEC filing
Filings Reviewed: 10-Q 2026-05-15 · 10-Q 2026-02-17 · 10-Q 2025-08-14 · 10-Q 2025-05-15 · 10-K 2025-12-19 · 10-K 2024-12-27
Rated on July 8, 2026 · How the Rating Is Built
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years no data
- More than 10% revenue growth is expected for the coming year 3,710.6%
- Share count grows by less than 3% a year 33.9%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -2,935.8%
- Gross margin at 40% or higher and without meaningful erosion no data
- Goodwill from acquisitions does not grow faster than revenue 0.0%
- Net debt below twice EBITDA failed
- Operating cash flow covers the profits of the last three years 33 m
- Return on capital at 15% or higher, or up versus two years ago no data
- Insiders hold at least 10% or are net buyers 17.4%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
3/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% -8.0%
- Exp. sales growth 3Y > 5% 459.3%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 459.3%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% –
- ROCE > 15% –
- Expected return > 10% 183.2%
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
Insiders
Insider Transactions
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | Kenyon Lawrence A | Chief Financial Officer | Buy | 101,010 | – | – |
| Aug 14, 2026 | Jahr Robert Charles | Chief Executive Officer | Buy | 151,515 | – | – |
| Aug 12, 2026 | Sukhtian Ghiath M. | Director | Buy | 2,525,252 | 0.99 | 2,499,999 |
| Jul 29, 2026 | Sukhtian Faisal Ghiath | Director | Buy | 95,398 | 1.05 | 99,996 |
The company
About the Company
Outlook Therapeutics, Inc. ist ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung und Vermarktung monoklonaler Antikörper für ophthalmologische Indikationen konzentriert.
- Employees
- 17
- Headquarters
- Iselin, NJ
- Address
- 111 S. Wood Avenue, 08830 Iselin, United States
- Phone
- 609 619 3990
- Website
- outlooktherapeutics.com
- IPO Date
- 05/13/2016
- ISIN
- US69012T3059
- Stock Split
- 1:20 on 03/14/2024
- Stock Split
- 1:8 on 03/18/2019
Management
| Name | Title | Birth Year |
|---|---|---|
| Robert Charles Jahr | President, CEO & Director | 1973 |
| Kevin Lundquist | CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer | 1968 |
| Joel Prieve | Senior Vice President of Licensing and M&A | – |
| Surendra Sharma M.D. | Senior Vice President of Medical Affairs | – |
| Jennifer M. Kissner Ph.D. | Senior Vice President of Clinical Development & Regulatory Affairs | – |
| Jedd Comiskey | Senior VP - Head of Europe | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
- 08/27/2026 Outlook Therapeutics, Inc. (OTLK): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Financial Statements and Exhibits SEC ↗
- 08/14/2026 Outlook Therapeutics, Inc. (OTLK): Other Events; Financial Statements and Exhibits SEC ↗
- 08/14/2026 Outlook Therapeutics, Inc. (OTLK): Results of Operations and Financial Condition; Financial Statements and Exhibits SEC ↗
- 08/12/2026 Outlook Therapeutics, Inc. (OTLK): Results of Operations and Financial Condition; Other Events; Financial Statements and Exhibits SEC ↗
- 07/24/2026 Outlook Therapeutics, Inc. (OTLK): Other Events; Financial Statements and Exhibits SEC ↗
- 07/23/2026 Outlook Therapeutics, Inc. (OTLK): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers SEC ↗
- 07/16/2026 Outlook Therapeutics, Inc. (OTLK): Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders; Financial Statements and Exhibits SEC ↗
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.